Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) was the recipient of a large decline ...
More phase III data coursed through the annual American Society of Clinical Oncology (ASCO) conferen...
HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Protagonist Thera...
In the latest quarter, 9 analysts provided ratings for Protagonist Therapeutics (NASDAQ:PTGX), showc...
More phase III data coursed through the annual American Society of Clinical Oncology (ASCO) conferen...